205 related articles for article (PubMed ID: 37562974)
21. Cumulative Roles for Epstein-Barr Virus, Human Endogenous Retroviruses, and Human Herpes Virus-6 in Driving an Inflammatory Cascade Underlying MS Pathogenesis.
Meier UC; Cipian RC; Karimi A; Ramasamy R; Middeldorp JM
Front Immunol; 2021; 12():757302. PubMed ID: 34790199
[TBL] [Abstract][Full Text] [Related]
22. Activation of DNA methyltransferase 3a by Epstein-Barr nuclear antigen 1 in gastric carcinoma.
Song H; Zhang Y; Liu J; Liu W; Luo B
Dig Liver Dis; 2022 Jul; 54(7):973-983. PubMed ID: 34215536
[TBL] [Abstract][Full Text] [Related]
23. Epstein-Barr virus nuclear antigen 1 interacts with Nm23-H1 in lymphoblastoid cell lines and inhibits its ability to suppress cell migration.
Murakami M; Lan K; Subramanian C; Robertson ES
J Virol; 2005 Feb; 79(3):1559-68. PubMed ID: 15650182
[TBL] [Abstract][Full Text] [Related]
24. Cytolytic CD4(+)-T-cell clones reactive to EBNA1 inhibit Epstein-Barr virus-induced B-cell proliferation.
Nikiforow S; Bottomly K; Miller G; Münz C
J Virol; 2003 Nov; 77(22):12088-104. PubMed ID: 14581546
[TBL] [Abstract][Full Text] [Related]
25. Carcinoma-risk variant of EBNA1 deregulates Epstein-Barr Virus episomal latency.
Dheekollu J; Malecka K; Wiedmer A; Delecluse HJ; Chiang AK; Altieri DC; Messick TE; Lieberman PM
Oncotarget; 2017 Jan; 8(5):7248-7264. PubMed ID: 28077791
[TBL] [Abstract][Full Text] [Related]
26. Epstein-Barr virus EBNA1 protein regulates viral latency through effects on let-7 microRNA and dicer.
Mansouri S; Pan Q; Blencowe BJ; Claycomb JM; Frappier L
J Virol; 2014 Oct; 88(19):11166-77. PubMed ID: 25031339
[TBL] [Abstract][Full Text] [Related]
27. First Days in the Life of Naive Human B Lymphocytes Infected with Epstein-Barr Virus.
Pich D; Mrozek-Gorska P; Bouvet M; Sugimoto A; Akidil E; Grundhoff A; Hamperl S; Ling PD; Hammerschmidt W
mBio; 2019 Sep; 10(5):. PubMed ID: 31530670
[TBL] [Abstract][Full Text] [Related]
28. DNA ligand designed to antagonize EBNA1 represses Epstein-Barr virus-induced immortalization.
Yasuda A; Noguchi K; Minoshima M; Kashiwazaki G; Kanda T; Katayama K; Mitsuhashi J; Bando T; Sugiyama H; Sugimoto Y
Cancer Sci; 2011 Dec; 102(12):2221-30. PubMed ID: 21910783
[TBL] [Abstract][Full Text] [Related]
29. Human CD4(+) T lymphocytes consistently respond to the latent Epstein-Barr virus nuclear antigen EBNA1.
Münz C; Bickham KL; Subklewe M; Tsang ML; Chahroudi A; Kurilla MG; Zhang D; O'Donnell M; Steinman RM
J Exp Med; 2000 May; 191(10):1649-60. PubMed ID: 10811859
[TBL] [Abstract][Full Text] [Related]
30. Small molecule inhibition of Epstein-Barr virus nuclear antigen-1 DNA binding activity interferes with replication and persistence of the viral genome.
Lee EK; Kim SY; Noh KW; Joo EH; Zhao B; Kieff E; Kang MS
Antiviral Res; 2014 Apr; 104():73-83. PubMed ID: 24486954
[TBL] [Abstract][Full Text] [Related]
31. Potential cellular functions of Epstein-Barr Nuclear Antigen 1 (EBNA1) of Epstein-Barr Virus.
Westhoff Smith D; Sugden B
Viruses; 2013 Jan; 5(1):226-40. PubMed ID: 23325328
[TBL] [Abstract][Full Text] [Related]
32. Association of Epstein-Barr virus latently expressed genes with multiple sclerosis.
Varvatsi D; Richter J; Tryfonos C; Pantzaris M; Christodoulou C
Mult Scler Relat Disord; 2021 Jul; 52():103008. PubMed ID: 34010765
[TBL] [Abstract][Full Text] [Related]
33. EBNA1.
Frappier L
Curr Top Microbiol Immunol; 2015; 391():3-34. PubMed ID: 26428370
[TBL] [Abstract][Full Text] [Related]
34. Structure-based design of small-molecule inhibitors of EBNA1 DNA binding blocks Epstein-Barr virus latent infection and tumor growth.
Messick TE; Smith GR; Soldan SS; McDonnell ME; Deakyne JS; Malecka KA; Tolvinski L; van den Heuvel APJ; Gu BW; Cassel JA; Tran DH; Wassermann BR; Zhang Y; Velvadapu V; Zartler ER; Busson P; Reitz AB; Lieberman PM
Sci Transl Med; 2019 Mar; 11(482):. PubMed ID: 30842315
[TBL] [Abstract][Full Text] [Related]
35. Seroreactivity against lytic, latent and possible cross-reactive EBV antigens appears on average 10 years before MS induced preclinical neuroaxonal damage.
Jons D; Grut V; Bergström T; Zetterberg H; Biström M; Gunnarsson M; Vrethem M; Brenner N; Butt J; Blennow K; Nilsson S; Kockum I; Olsson T; Waterboer T; Sundström P; Andersen O
J Neurol Neurosurg Psychiatry; 2024 Mar; 95(4):325-332. PubMed ID: 37802637
[TBL] [Abstract][Full Text] [Related]
36. Three pathways of Epstein-Barr virus gene activation from EBNA1-positive latency in B lymphocytes.
Rowe M; Lear AL; Croom-Carter D; Davies AH; Rickinson AB
J Virol; 1992 Jan; 66(1):122-31. PubMed ID: 1309242
[TBL] [Abstract][Full Text] [Related]
37. Epstein-Barr virus-encoded EBNA1 and ZEBRA: targets for therapeutic strategies against EBV-carrying cancers.
Daskalogianni C; Pyndiah S; Apcher S; Mazars A; Manoury B; Ammari N; Nylander K; Voisset C; Blondel M; Fåhraeus R
J Pathol; 2015 Jan; 235(2):334-41. PubMed ID: 25186125
[TBL] [Abstract][Full Text] [Related]
38. Epstein-Barr virus in multiple sclerosis.
Abdelrahman HS; Selim HS; Hashish MH; Sultan LI
J Egypt Public Health Assoc; 2014 Aug; 89(2):90-5. PubMed ID: 25162741
[TBL] [Abstract][Full Text] [Related]
39. Novel Epstein-Barr virus-like particles incorporating gH/gL-EBNA1 or gB-LMP2 induce high neutralizing antibody titers and EBV-specific T-cell responses in immunized mice.
Perez EM; Foley J; Tison T; Silva R; Ogembo JG
Oncotarget; 2017 Mar; 8(12):19255-19273. PubMed ID: 27926486
[TBL] [Abstract][Full Text] [Related]
40. Epstein-Barr virus latent infection and BAFF expression in B cells in the multiple sclerosis brain: implications for viral persistence and intrathecal B-cell activation.
Serafini B; Severa M; Columba-Cabezas S; Rosicarelli B; Veroni C; Chiappetta G; Magliozzi R; Reynolds R; Coccia EM; Aloisi F
J Neuropathol Exp Neurol; 2010 Jul; 69(7):677-93. PubMed ID: 20535037
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
